Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
By Chang Liu, H. Ginn, W. Dejnirattisai, P. Supasa, Beibei Wang, A. Tuekprakhon, Rungtiwa Nutalai, Daming Zhou, A. Mentzer, Yuguang Zhao and 48 more. Cell, 2021
742 citations recorded by the source corpus.
Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/177e9902d230e3ce7eb54cb2776567ac508e3add
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022, positive): “…(https://www.cdc. gov/coronavirus/2019-ncov/variants/variant-classifications.html) and have led to successive waves of infection: first, Alpha (Supasa et al., 2021), second, Delta (Liu et al., 2021a), and then Omicron (Dejnirattisai et al., 2022) spread globally, becoming the dominant variants.”
- Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines (2022, background): “Interestingly, some of the mutations were already found in the previous VOC that helps in neutralizing antibodies.(15,16) Five different variants of SARS‐CoV‐2 have been considered VOC at different times.”
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2022, positive): “Delta mutations: L452R in front of the neck, and T478K on the far side of the left shoulder, fall just peripheral to the ACE2 binding footprint (Figure 2F; Liu et al., 2021a).”
- Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies (2022, background): “However, for another example (target 7ORA (39), 197 Figure 2D), IgFold more accurately predicts the CDR H3 loop structure (RMSDH3 = 1.”